Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Short-term Investments (2023 - 2025)

Beta Bionics (BBNX) has disclosed Short-term Investments for 3 consecutive years, with $187.5 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 156.41% to $187.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $187.5 million through Dec 2025, up 156.41% year-over-year, with the annual reading at $187.5 million for FY2025, 156.41% up from the prior year.
  • Short-term Investments hit $187.5 million in Q4 2025 for Beta Bionics, down from $190.2 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $214.6 million in Q2 2025 to a low of $70.2 million in Q4 2023.
  • Historically, Short-term Investments has averaged $154.1 million across 3 years, with a median of $188.3 million in 2025.
  • Biggest five-year swings in Short-term Investments: rose 4.22% in 2024 and later surged 156.41% in 2025.
  • Year by year, Short-term Investments stood at $70.2 million in 2023, then grew by 4.22% to $73.1 million in 2024, then soared by 156.41% to $187.5 million in 2025.
  • Business Quant data shows Short-term Investments for BBNX at $187.5 million in Q4 2025, $190.2 million in Q3 2025, and $214.6 million in Q2 2025.